Semaglutide consistently reduces both fasting and postprandial glucose levels across SUSTAIN 1-5 clinical trials

被引：0
|
作者：
Cariou, B. [1 ]
Unger, J. [2 ]
Jodar, E. [3 ]
Birch, S. [4 ]
Tadayon, S. [4 ]
Aroda, V. R. [5 ]
机构：
[1] CHU Nantes, Inst Thorax, Nantes, France
[2] Catalina Res Inst, Chino, CA USA
[3] Hosp Univ Quironsalud Madrid, Fac Ciencias Salud, Madrid, Spain
[4] Novo Nordisk AS, Soborg, Denmark
[5] MedStar Hlth Res Inst, Hyattsville, MD USA
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
818
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 27 条
  • [21] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    DIABETOLOGIA, 2017, 60 : S378 - S379
  • [22] Time spent in glucose control after initiating tirzepatide vs comparators: exploratory analysis of fasting serum glucose in SURPASS 1-5 trials
    Batterham, R. L.
    Rosenstock, J.
    Garvey, W. T.
    Liu, M.
    Chen, Y.
    Bergman, B. K.
    Hemmingway, A.
    Thieu, V. T.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S341 - S342
  • [23] Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials
    Aroda, Vanita R.
    Capehorn, Matthew S.
    Chaykin, Louis
    Frias, Juan P.
    Lausvig, Nanna L.
    Macura, Stanislava
    Luedemann, Jorg
    Madsbad, Sten
    Rosenstock, Julio
    Tabak, Omur
    Tadayon, Sayeh
    Bain, Stephen C.
    DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 303 - 314
  • [24] More semaglutide-treated subjects achieved HbA1c below 7% without weight gain, hypoglycaemia, and gastrointestinal adverse events vs comparators in the SUSTAIN 1-5 trials
    DeVries, J. H.
    Desouza, C.
    Bellary, S.
    Unger, J.
    Bangsgaard, E. O.
    Zacho, J.
    Woo, V.
    DIABETOLOGIA, 2017, 60 : S376 - S376
  • [25] Greater Reductions in HbA1c and Body Weight with Once-Weekly Semaglutide vs. Comparators across Baseline BMI Subgroups: A Post Hoc Analysis of SUSTAIN 1-5 and 7-10
    Aroda, Vanita R.
    Frenkel, Ofir
    Frias, Juan P.
    Hindsberger, Charlotte
    Gylvin, Silas H.
    Le Roux, Carel
    Madsbad, Sten
    DIABETES, 2020, 69
  • [26] Contribution of fasting and postprandial plasma glucose to HbA1c in people with type 2 diabetes on basal-bolus insulin: a meta-analysis of insulin lispro clinical trials
    Liao, B.
    Chen, Y.
    Chigutsa, F.
    de Oliveira, C. Piras
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S332 - S332
  • [27] Fasting and postprandial plasma glucose contributions to hemoglobin A1c and time in range in people with diabetes on multiple daily injection insulin therapy: Results from the PRONTO-T1D and PRONTO-T2D clinical trials
    de Oliveira, Carolina Piras
    Dellva, Mary Anne
    Bue-Valleskey, Juliana
    Chang, Annette M.
    Liao, Birong
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2024, 38 (01)
123